The estimated Net Worth of Linda Liu is at least $74.6 mil dollars as of 27 November 2019. Linda Liu owns over 55,234 units of Nextcure Inc stock worth over $74,577 and over the last 5 years he sold NXTC stock worth over $0. In addition, he makes $0 as Senior Vice President - Research at Nextcure Inc.
Linda has made over 1 trades of the Nextcure Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 55,234 units of NXTC stock worth $41,426 on 27 November 2019.
The largest trade he's ever made was exercising 55,234 units of Nextcure Inc stock on 27 November 2019 worth over $41,426. On average, Linda trades about 13,809 units every 0 days since 2019. As of 27 November 2019 he still owns at least 55,234 units of Nextcure Inc stock.
You can see the complete history of Linda Liu stock trades at the bottom of the page.
DR. Linda Liu PhD serves as Senior Vice President - Research of the Company. Prior to joining NextCure, Dr. Liu held several positions at Amplimmune from 2007 to August 2015, including Executive Director of Translational Science/Scientific Affairs and Vice President of New Product Development from January 2013 to August 2015. She served as a Senior Director of Biological Product Development at MaxCyte, Inc., a clinical stage biotechnology company aimed at commercializing cell loading technology, from 2000 to 2007 and as a Senior Scientist at Osiris Therapeutics, Inc. from 1999 to 2000. Dr. Liu received a B.S. in virology and molecular biology from Wuhan University in China and a Ph.D. in virology and cell biology from the University of Texas at Austin. She conducted her postdoctoral training in tumor cell biology at the St. Jude Children's Research Hospital.
Linda Liu is 53, he's been the Senior Vice President - Research of Nextcure Inc since 2018. There are 18 older and 2 younger executives at Nextcure Inc. The oldest executive at Nextcure Inc is David Kabakoff, 72, who is the Independent Chairman of the Board.
Linda's mailing address filed with the SEC is C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705.
Over the last 6 years, insiders at Nextcure Inc have traded over $0 worth of Nextcure Inc stock and bought 1,475,000 units worth $25,387,500 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Chau Quang Khuong y Timothy M Shannon. On average, Nextcure Inc executives and independent directors trade stock every 48 days with the average trade being worth of $233,653. The most recent stock trade was executed by Kevin N. Heller on 14 July 2020, trading 27,229 units of NXTC stock currently worth $48,195.
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
Nextcure Inc executives and other stock owners filed with the SEC include: